VERTEPORFIN

BRAND NAME	VISUDYNE
DRUG CLASS	Light-activated photosensitiser (for photodynamic therapy)
AVAILABILITY	Vial contains 15 mg of verteporfin. Also contains lactose, dimyristoylphatidylcholine, egg phosphatidylglycerol sodium, ascorbyl palmitate and butylated hydroxytoluene.[1]
	Extravasation may cause severe pain, inflammation, swelling or discolouration of the injection site. If extravasation occurs stop the infusion and apply a cold compress. Protect from light until swelling and discolouration have faded.[1]
pH	No information
PREPARATION	Reconstitute the vial with 7 mL of water for injections to make a 2 mg/mL solution. The solution is opaque and dark green.[1]
STABILITY	Vial: store below 25 °C. Protect from light.[1] Infusion solution: protect from light and use within 4 hours.[1]
ADMINISTRATION	
IM injection	Not recommended
SUBCUT injection	Not recommended
IV injection	Not recommended
IV infusion	Dilute the dose in glucose 5% to a final volume of 30 mL. Infuse over 10 minutes.[1] To avoid extravasation, use the largest possible arm vein, preferably the antecubital vein and establish a free flowing IV line before starting the infusion.[1] Light activation of verteporfin is required 15 minutes after the start of the infusion.[1]
COMPATIBILITY	
Fluids	Glucose 5%[1]
Y-site	Do not mix with other medicines[1]
INCOMPATIBILITY	
Fluids	Sodium chloride 0.9%[1]
Drugs	No information
SPECIAL NOTES	Patients are photosensitive for up to 48 hours after the infusion and must avoid sunlight or bright indoor lighting.[1] Back and chest pain may occur during the infusion.[1] Anaphylactic reactions have been reported.[1] If material is spilled, contain and wipe up with a damp cloth. Avoid eye and skin contact.[1]

REFERENCES

1. Product information. Available from www.tga.gov.au. Accessed 03/07/2019.